Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography
This trial is active, not recruiting.
|Sponsor||Association for Innovation and Biomedical Research on Light and Image|
|Start date||September 2015|
|End date||April 2016|
|Trial size||62 participants|
|Trial identifier||NCT02391558, 4C-2015-07|
Clinical evaluation of noninvasive OCT Angiography using a Zeiss OCT Prototype to replace fluorescein angiography.
Comparison between examination techniques on the detection of morphological changes in the retina (such as vessels morphology, vascular ischemia, retinal neovascularization, choroidal neovascularization, and other vascular abnormalities).
time frame: Single Visit
Male or female participants from 18 years up to 90 years old.
Inclusion Criteria: - All patients with clinical indication for fluorescein angiography in their clinical practice Exclusion Criteria: - Subjects with a pacemaker of similarly critical electronic device - Subjects with severe ocular media opacities - Subjects with corneal abnormalities
|Official title||Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography|
|Description||Fluorescein angiography (FA) is the standard and generally accepted method to identify vascular features in the retina, detecting capillary dropout and neovessel growth. Its value is undeniable and is a routine ophthalmological examination. However, it requires intravenous injection of fluorescein, which can cause nausea, vomiting and, rarely, anaphylaxis and death. New OCT angiography methods can detect, noninvasively red blood cells flow and, therefore, identify well the retinal vasculature. It is crucial and of major interest to evaluate the clinical utility of this new methodology comparing this information with the one obtained from fluorescein angiography.|
Call for more information